Wedbush

Dan Ives of Wedbush raises the price target for Microsoft to $425, citing advancements in AI and new custom computing chips.

Dan Ives, tech analyst at Wedbush, said: ‘Apple delivered solid results with services the shining star while iPhone revenues met expectations.

Day One Biopharmaceuticals ( had its price objective reduced by Wedbush from $39.00 to $35.00 in a note issued to investors on Tuesday, reports.

Finally, Wedbush reaffirmed a “neutral” rating and issued a $140.00 target price on shares of International Business Machines in a report on Thursday, July 20th.

Finally, Wedbush reiterated an “outperform” rating on shares of Evolent Health in a research report on Thursday, November 16th.

Finally, Wedbush Securities Inc. purchased a new stake in Enphase Energy in the 1st quarter worth about $434,000.

Finally, Wedbush Securities Inc. raised its position in Triton International by 4.4% during the 3rd quarter.

One investment firm known for years as a Netflix bear, Wedbush Securities, has become a bull.

Tesla Poised to Benefit From Musk Stepping Down as Twitter Chief Executive, Wedbush Say.

Wedbush also issued estimates for Brinker International’s FY2025 earnings at $3.81 EPS.

Wedbush began coverage on shares of Okta in a report on Wednesday, December 14th.

Wedbush currently has a “Outperform” rating and a $95.00 target price on the stock.

Wedbush Downgraded SVB Prior To Collapse, Other Regional Banks Present Opportunitiesbenzinga.

Wedbush initiated coverage on Celsius in a research note on Monday, October 10th.

Wedbush reaffirmed a “neutral” rating and set a $85.00 price objective on shares of CarMax in a report on Thursday, August 17th.

Wedbush reaffirmed a “neutral” rating on shares of Genuine Parts in a report on Friday, February 24th.

Wedbush reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Vigil Neuroscience in a research report on Monday, April 3rd.

Wedbush reaffirmed an “outperform” rating and issued a $270.00 target price on shares of Visa in a research report on Thursday, August 31st.

Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Infosys in a report on Monday, September 18th.

Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Apogee Therapeutics in a research report on Monday, November 13th.